Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impressive $290 million in ...

Biopharma startup Metsera turned heads in April when it emerged from stealth, announcing $290 million in funding from prestigious backers—an all-star roster of scientists and executives—and a ...

Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss ...

BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and ...

(RTTNews) - Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss ...

Recommended Reading A gene editing biotech’s struggles end with reverse merger Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million ...

Metsera gains high-quality, efficient, large-scale manufacturing capabilities for its portfolio to enable rapid product development and anticipated commercial launches Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals (NASDAQ:AMRX) entered agreement with Metsera to enable development and large-scale supply of a portfolio of new weight loss medicines globally. Amneal will construct ...

Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, ...

The firm also reaffirmed its Buy rating on the stock. This adjustment follows recent developments regarding Amprius's collaboration with Metsera, which marks the company's entry into the GLP1 space.